{"slug":"semax-glp-1","verification":{"valid":true,"entries":2,"head":"17fc0f4fdd8a323892c083d02bb97ce6e60c15f4f7b8e7249de63fcbe1a2e6d2"},"energy":{"passes":2,"tokens_in":15630,"tokens_out":2865,"tokens_total":18495,"cost_usd":0,"models":{"grok/grok-4.3":1,"owner":1},"head":"17fc0f4fdd8a323892c083d02bb97ce6e60c15f4f7b8e7249de63fcbe1a2e6d2"},"provenance":[{"ts":"2026-06-30T00:12:07.790Z","model":"grok/grok-4.3","action":"write","prompt":"","input":"Write a data-first, evidence-graded article: Semax for Glp 1\nSlug: semax-glp-1\nAudience: readers researching peptide evidence for this specific condition or drug cross.\nRules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate human trials from rat studies from Reddit/X anecdotes. No medical claims. Repair-vs-suppression framing. register: source_ledger.\n\nENRICHMENT BRIEF (binding section logic — one ## per compound):\n{\"voice\":\"enrichment\",\"article_shape\":\"single_focus\",\"condition\":null,\"condition_key\":null,\"primary_peptide\":null,\"peptides_in_scope\":[{\"id\":\"semax\",\"name\":\"Semax\"}],\"drugs_in_scope\":[\"glp1-agonists\"],\"weight_sensitive\":false,\"stimulant_context\":false,\"breaking_down\":{\"section_title\":\"What's breaking down\",\"degenerative_why\":[],\"degenerative_layers\":[],\"note\":\"No condition profile matched — infer degeneration layers from slug/title and ledger claims.\"},\"peptide_chains\":[{\"peptide\":\"semax\",\"name\":\"Semax\",\"section_title\":\"Why Semax might help you\",\"layer\":\"neural / cognitive\",\"steps\":[\"**What keeps failing:** BDNF decline, stimulant-induced neuro stress, cognitive fatigue after dopamine load.\",\"**What Semax is studied to do:** Studied for BDNF and neural support — building connections, not sedating symptoms.\",\"**Therefore for you:** If that layer is part of your problem, Semax is discussed because it targets repair (neural / cognitive) — not because it masks pain.\"],\"prose\":\"1. **What keeps failing:** BDNF decline, stimulant-induced neuro stress, cognitive fatigue after dopamine load.\\n2. **What Semax is studied to do:** Studied for BDNF and neural support — building connections, not sedating symptoms.\\n3. **Therefore for you:** If that layer is part of your problem, Semax is discussed because it targets repair (neural / cognitive) — not because it masks pain.\"}],\"drug_chains\":[{\"drug\":\"glp1-agonists\",\"name\":\"GLP-1 agonists (class)\",\"section_title\":\"Why GLP-1 agonists (class) matters for you\",\"steps\":[\"**Drug:** GLP-1 ","response":"{\n  \"slug\": \"semax-glp-1\",\n  \"title\": \"Semax and GLP-1 Agonists: Graded Evidence on Neural and Metabolic Layers\",\n  \"body\": \"## What's breaking down\\n\\nNo single clinical condition profile matches the slug. Layers are inferred from available peptide and drug data: cognitive fatigue, BDNF decline under dopamine or metabolic stress, and potential neural support needs during GLP-1 agonist use. GLP-1 agonists primarily act on metabolic pathways. Semax is studied for neural repair pathways.\\n\\nBreakdown occurs when repair processes lag behind daily demands on the brain's plasticity systems. BDNF levels support neuron maintenance and new connections. Declines here link to slower recovery from stress or fatigue in available models.\\n\\n## Why Semax might help you\\n\\n1. What keeps failing: BDNF decline, stimulant-induced neuro stress, cognitive fatigue after dopamine load.\\n2. What Semax is studied to do: Studied for BDNF and neural support — building connections, not sedating symptoms.\\n3. Therefore for you: If that layer is part of your problem, Semax is discussed because it targets repair (neural / cognitive) — not because it masks pain.\\n\\nIf GLP-1 agonist use coincides with reports of mental fog or focus issues, the neural layer becomes relevant. Semax research centers on upregulating BDNF protein and related gene expression rather than blocking signals.\\n\\n## Why GLP-1 agonists (class) matters for you\\n\\n1. Drug: GLP-1 agonists (class).\\n2. What it does: Metabolic benefit vs gut slowing / muscle loss tradeoffs at rapid weight loss.\\n3. Therefore for you: This drug supports metabolism through appetite regulation and insulin effects. It does not directly target neural repair pathways. Any cognitive overlap would be indirect via systemic changes.\\n\\nGLP-1 agonists reduce caloric intake and improve glycemic control. Tradeoffs noted in data include potential muscle loss during fast weight reduction, which could indirectly affect overall recovery capacity.\\n\\n## How these fi","tokens_in":15630,"tokens_out":2865,"cost":0,"prev":"genesis","hash":"f9382282c1457a0473e99f495d4f421bdc3b01b7deb751ac7ea9bdb0ce66f779"},{"ts":"2026-07-17T02:41:53.647Z","model":"owner","action":"voxel_divide","prompt":"","input":"semax-glp-1","response":"28 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"f9382282c1457a0473e99f495d4f421bdc3b01b7deb751ac7ea9bdb0ce66f779","hash":"17fc0f4fdd8a323892c083d02bb97ce6e60c15f4f7b8e7249de63fcbe1a2e6d2"}]}